000			a
999			_c16216 _d16216
003			OSt
005			20220204105118.0
008			220204b xxu||||| |||| 00| 0 eng d
040			_aAIKTC-KRRC _cAIKTC-KRRC
100			_915847 _aMisbahuddin M. Rafeeq
245			_aSodium-glucose cotransporter-2 inhibitors as modulator of dipeptidyl peptidase-4 in diabetes
250			_aVol.55(4), Oct-Dec
260			_aKarnataka _bAssociation of Pharmaceutical Teachers of India (APTI) _c2021
300			_a1008-1016p.
520			_aBackground: Genetic disorders such as diabetes have severe implications on human health. Mutation or aberrant activity of different proteins are associated with diabetes. The hyperactivation of the peptidase function of dipeptidyl peptidase-4 (DPP4) strongly correlates with the elevated level of blood glucose in diabetic patients. Aim: Preventing the activity of DPP4 by small molecule modulators is an excellent approach that proposes to curb the aggressiveness of diabetes. Blocking the DPP4 function quantitatively raises glucagon-like peptide 1 (GLP-1) in the blood that finally lowers the level of glucose in circulating fluids. Materials and Methods: In this study, we have conducted an elaborate investigations of the sequence-based structural properties of DPP4 protein by using various computational methods in order to find protein’s antigenic and drug-binding regions. Results: Using the dataset of sodium-glucose transport protein 2 (SGLT2) inhibitors, we have identified a set of molecules that are predicted to bind DPP4. We have characterized the dipeptide ubenimex as the most potential modulator of DPP4. Conclusion: Based on the findings of current study, we concluded that our study has decoded the inhibitory module of DPP4 by the approach of structure-guided drug identification.
650		0	_94639 _aPHARMACEUTICS
700			_915848 _aHaque, Shahnaz
773	0		_x0019-5464 _tIndian journal of pharmaceutical education and research _dBengluru Association of Pharmaceutical Teachers of India (APTI)
856			_uhttps://www.ijper.org/sites/default/files/IndJPhaEdRes-55-4-1008.pdf _yClick here
942			_2ddc _cAR